AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8742561 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 1441
Study 1579627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol associated drinks consumed
Number of subjects: 40
Study 1579627 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol associated drinks consumed
Number of subjects: 40
Study 1579627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol associated drinks held
Number of subjects: 40
Study 1579627 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol associated drinks held
Number of subjects: 40
Study 3893512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (200 mg thrice daily for 4 weeks)
Number of subjects: 9
Study 3893512 — intervention group
Group type: COMPARATOR
Intervention: Control or placebo
Number of subjects: 9
Study 31153114 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl treatment for 20 minutes
Number of subjects: 15
Study 31153114 — intervention group
Group type: COMPARATOR
Intervention: Heat treatment (200 °C)
Number of subjects: 15
Study 31153114 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl treatment followed by heat treatment (200 °C)
Number of subjects: 15
Study 31153114 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-Raman spectroscopy after NaOCl treatment
Number of subjects: 15
Study 30838382 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thoracic surgery (VATS)
Number of subjects: 206
Study 30838382 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 206
Study 30838382 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 206
Study 27783276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years, with PSL starting at 40 mg/day and tapering, and MZR given once-a-day at 150 mg (group 1) or 3-times-a-day at 50 mg (group 2).
Number of subjects: 37
Study 27783276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years.
Number of subjects: 37
Study 26392095 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 206
Study 26392095 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 206
Study 26392095 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Number of subjects: 206
Study 24071924 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual movement observation condition (MovOb)
Number of subjects: 98
Study 24071924 — intervention group
Group type: COMPARATOR
Intervention: Nonobservation condition (NonOb)
Number of subjects: 98
Study 21816786 — intervention group
Group type: EXPERIMENTAL
Intervention: GW501516 (2.5 mg/d)
Number of subjects: 13
Study 19688104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study 19688104 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 17023230 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg
Number of subjects: 338
Study 17023230 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg
Number of subjects: 338
Study 17023230 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg
Number of subjects: 338
Study 17023230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 15292386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-paclitaxel (ET) chemotherapy
Number of subjects: 297
Study 15292386 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-cyclophosphamide (EC) chemotherapy
Number of subjects: 297
Study 11356585 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 45
Study 11356585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9146779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin 6 mg/kg
Number of subjects: 6
Study 9146779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin 1 mg/kg
Number of subjects: 6
Study 9146779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (both dosages)
Number of subjects: 6
Study 9146779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin
Number of subjects: 6
Study 8190679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral ketorolac
Number of subjects: 176
Study 8190679 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of IM morphine
Number of subjects: 176
Study 8190679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of IM morphine
Number of subjects: 176
Study 8190679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 3372704 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Number of subjects: 56
Study 31667935 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS)
Number of subjects: 24
Study 31667935 — intervention group
Group type: COMPARATOR
Intervention: Head lift exercises
Number of subjects: 24
Study 30091317 — intervention group
Group type: EXPERIMENTAL
Intervention: Early targeted physical rehabilitation with standard sepsis treatment during hospitalization
Number of subjects: 40
Study 30091317 — intervention group
Group type: COMPARATOR
Intervention: Standard sepsis treatment
Number of subjects: 40
Study 27235957 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music
Number of subjects: 159
Study 23767987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness with Metta Training Program (MMTP) retreat
Number of subjects: 44
Study 23767987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 24137215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐0.5 μg/kg/h continuous intravenous infusion for 12 h)
Number of subjects: 162
Study 24137215 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline and isopropylphenol (2‐4 mg/kg/h intravenous infusion for postoperative sedation)
Number of subjects: 162
Study 24137215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 162
Study 24137215 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline and isopropylphenol)
Number of subjects: 162
Study 21562445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procaine (2 g/24 h) for 72 hours
Number of subjects: 46
Study 21562445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19485592 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral treatment (FCBT; N = 47) with exposure tasks
Number of subjects: 86
Study 19485592 — intervention group
Group type: COMPARATOR
Intervention: Family education, support, and attention (FESA; N = 39)
Number of subjects: 86
Study 16820589 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin (pravastatin 40 mg/d)
Number of subjects: 60
Study 16820589 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1 blockade (irbesartan 150 mg/d)
Number of subjects: 60
Study 16820589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statin and AT1 blocker (same dosages)
Number of subjects: 60
Study 16820589 — intervention group
Group type: COMPARATOR
Intervention: Control (without inhibition of renin‐angiotensin system or statin)
Number of subjects: 60
Study 16820589 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin, AT1 blocker, and their combination
Number of subjects: 60
Study 12759324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate (10 mg daily)
Number of subjects: 373
Study 12759324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate alone (10 mg daily)
Number of subjects: 373
Study 12759324 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy alone
Number of subjects: 373
Study 12759324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with hormone replacement and alendronate
Number of subjects: 373
Study 12759324 — intervention group
Group type: COMPARATOR
Intervention: All therapies (combination, alendronate, hormone replacement)
Number of subjects: 373
Study 11317168 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album praeparatum mali (Iscador M)
Number of subjects: 92
Study 11317168 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album praeparatum pini (Iscador P)
Number of subjects: 92
Study 9117313 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctolog (trimebutine suppository) applied immediately after haemorrhoidectomy
Number of subjects: 160
Study 9117313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suppository)
Number of subjects: 160
Study 8420520 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 10
Study 8420520 — intervention group
Group type: COMPARATOR
Intervention: Placebo anesthesia (Vaseline)
Number of subjects: 10
Study 8420520 — intervention group
Group type: COMPARATOR
Intervention: Xylocaine (lidocaine) anesthesia
Number of subjects: 10
Study 2445114 — intervention group
Group type: EXPERIMENTAL
Intervention: dicumarol
Number of subjects: 88
Study 2445114 — intervention group
Group type: COMPARATOR
Intervention: no anticoagulant treatment (control)
Number of subjects: 88
Study 28514231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) combined with knee joint mobilization
Number of subjects: 44
Study 28514231 — intervention group
Group type: COMPARATOR
Intervention: Biomedical education with knee joint mobilization
Number of subjects: 44
Study 27043264 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week outpatient-based exercise and education program
Number of subjects: 63
Study 27043264 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 63
Study 25012288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 23437933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention
Number of subjects: 1483
Study 23437933 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 1483
Study 23437933 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1483
Study 23437933 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1483
Study 16200817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg once daily, with fluticasone propionate‐salmeterol, 250 microg twice daily
Number of subjects: 14
Study 16200817 — intervention group
Group type: COMPARATOR
Intervention: Placebo, with fluticasone propionate‐salmeterol, 250 microg twice daily
Number of subjects: 14
Study 16200817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg once daily, with fluticasone propionate alone, 250 microg twice daily
Number of subjects: 14
Study 16200817 — intervention group
Group type: COMPARATOR
Intervention: Placebo, with fluticasone propionate alone, 250 microg twice daily
Number of subjects: 14
Study 12742470 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose cyclosporine, fixed-dose sirolimus, and corticosteroids
Number of subjects: 771
Study 12742470 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose cyclosporine and trough concentration controlled sirolimus with corticosteroids
Number of subjects: 771
Study 12742470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and steroids without calcineurin inhibitors
Number of subjects: 771
Study 9862578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin D positivity in oestrogen receptor-positive cases (57%)
Number of subjects: 162
Study 9862578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cath D levels in Cath D-positive tumour epithelial cells
Number of subjects: 162
Study 9862578 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year overall survival rate in Cath D-positive patients
Number of subjects: 162
Study 9862578 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to progression based on Cath D content
Number of subjects: 162
Study 8588793 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal motion (condition A)
Number of subjects: 40
Study 8588793 — intervention group
Group type: COMPARATOR
Intervention: Vertical motion (condition B)
Number of subjects: 40
Study 8588793 — intervention group
Group type: COMPARATOR
Intervention: Supine position with vertical motion (condition C)
Number of subjects: 40
Study 8588793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean motion exposure times for moderate nausea in Experiment 1: A) 9.0 min.; B) 22.4 min.;
Number of subjects: 40
Study 8588793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean motion exposure times for moderate nausea in Experiment 2: A) 15.3 min.; B) 27.1 min.; C) 22.5 min.
Number of subjects: 40
Study 2212026 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional estimation of maxillary repositioning in the osteotomy line (Group I)
Number of subjects: 24
Study 2212026 — intervention group
Group type: COMPARATOR
Intervention: Measurements from a bone mark on the forehead to the incisor edges (Group II)
Number of subjects: 24
Study 484501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quinidine
Number of subjects: 18
Study 484501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31918761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula containing exogenous ketones (beta-hydroxybutyrate)
Number of subjects: 0
Study 31918761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27068845 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite STSG over ADM
Number of subjects: 52
Study 27068845 — intervention group
Group type: COMPARATOR
Intervention: STSG alone
Number of subjects: 52
Study 27068845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 24472436 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 1441
Study 24472436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1441
Study 24472436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1441
Study 23103596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg
Number of subjects: 300
Study 23103596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 50 mg
Number of subjects: 300
Study 23103596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 100 mg
Number of subjects: 300
Study 23103596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch tablet)
Number of subjects: 300
Study 19944891 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin extended release (2-g single dose)
Number of subjects: 749
Study 19944891 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (875 mg/125 mg every 12 hours for 10 days)
Number of subjects: 749
Study 19944891 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin extended release
Number of subjects: 749
Study 19944891 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 749
Study 19043151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Number of subjects: 86
Study 19043151 — intervention group
Group type: COMPARATOR
Intervention: Manualised Good Clinical Care (GCC)
Number of subjects: 86
Study 16000669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordless screwdriver and FM Extractor
Number of subjects: 19
Study 16000669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordless screwdriver and Trainer's Angel
Number of subjects: 19
Study 16000669 — intervention group
Group type: COMPARATOR
Intervention: Cutting tools
Number of subjects: 19
Study 12501873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 364
Study 12501873 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g once daily
Number of subjects: 364
Study 10511784 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol)
Number of subjects: 40
Study 10511784 — intervention group
Group type: COMPARATOR
Intervention: IA (halothane)
Number of subjects: 40
Study 7788230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced TurboFLASH (DCETF) imaging
Number of subjects: 41
Study 7788230 — intervention group
Group type: COMPARATOR
Intervention: T2 weighted spin echo (T2WSE) imaging
Number of subjects: 41
Study 2343722 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.075 mg/kg
Number of subjects: 61
Study 2343722 — intervention group
Group type: EXPERIMENTAL
Intervention: dixyrazine 0.25 mg/kg
Number of subjects: 61
Study 2343722 — intervention group
Group type: COMPARATOR
Intervention: no antiemetic prophylaxis (control)
Number of subjects: 61
Study 7429342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (20 mg/kg body weight/24 h)
Number of subjects: 15
Study 7429342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (15 g/m2/24 h)
Number of subjects: 15
Study 7429342 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic supplement (Pancrelipase, 27 capsules per day)
Number of subjects: 15
Study 7429342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and sodium bicarbonate
Number of subjects: 15
Study 31604621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 279
Study 31604621 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (PVP-I)
Number of subjects: 279
Study 31594719 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose (100 μg) of atorvastatin
Number of subjects: 47
Study 31594719 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose (10 mg) of atorvastatin
Number of subjects: 47
Study 31594719 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 47
Study 27246653 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (32 sessions)
Number of subjects: 211
Study 27246653 — intervention group
Group type: COMPARATOR
Intervention: Control (physical education as usual)
Number of subjects: 211
Study 27246653 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 211
Study 25583256 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase-inhibitor (C1-INH) administered at 1,000 international units (IU) intravenously
Number of subjects: 57
Study 25583256 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and antihistamines (historical control)
Number of subjects: 57
Study 24164846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame group (40 g/day sesame by oral administration for 2 months)
Number of subjects: 50
Study 24164846 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study 21129058 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 62
Study 21129058 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 62
Study 21129058 — intervention group
Group type: COMPARATOR
Intervention: FGAs
Number of subjects: 62
Study 19690579 — intervention group
Group type: EXPERIMENTAL
Intervention: Short interval (tests on consecutive days)
Number of subjects: 15
Study 19690579 — intervention group
Group type: COMPARATOR
Intervention: Long interval (tests spread over 20-30 days with 5-10 days between tests)
Number of subjects: 15
Study 19690579 — intervention group
Group type: COMPARATOR
Intervention: Long interval (tests spread over 20-30 days)
Number of subjects: 15
Study 19690579 — intervention group
Group type: EXPERIMENTAL
Intervention: First test
Number of subjects: 15
Study 17546381 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical carious removal
Number of subjects: 90
Study 17546381 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 90
Study 17546381 — intervention group
Group type: COMPARATOR
Intervention: Traditional rotary instrument
Number of subjects: 90
Study 14749545 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlang model for CsA
Number of subjects: 80
Study 14749545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimation using Erlang model
Number of subjects: 80
Study 14749545 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other models (time-lag, zero-order, first-order, Weibull)
Number of subjects: 80
Study 11380323 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole, clarithromycin and metronidazole (PCM)
Number of subjects: 199
Study 11380323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, clarithromycin and eicosapen (PCE)
Number of subjects: 199
Study 9916901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 12
Study 9916901 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 12
Study 9916901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 12
Study 7995010 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day nicorandil (10 mg orally twice a day)
Number of subjects: 12
Study 7995010 — intervention group
Group type: COMPARATOR
Intervention: 7-day intermittent nitroglycerin patch (10 mg for 16 of 24 hours)
Number of subjects: 12
Study 2662829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 80 mg/day
Number of subjects: 15
Study 2662829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxiphylline 1,200 mg/day
Number of subjects: 15
Study 2662829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4919019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 4919019 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 0
Study 29939049 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim buprenorphine treatment (IBT; n = 25)
Number of subjects: 50
Study 29939049 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC; n = 25)
Number of subjects: 50
Study 28043055 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 29